CareFusion Makes Its First Steps Count

Just six months removed from Cardinal Health, CareFusion is making headlines with new products, anti-trust lawsuits and signficant acquisitions. The three individual events reflect the aggressive attitude CareFusion executives intend to carry now that they’re free from Cardinal Health.

CareFusion Corp. – just six months removed from spinning out of Cardinal Health Inc. – grabbed headlines not twice but three times last month. [See Deal] First, the company went to war with Medtronic PLC, announcing its plans to launch a kyphoplasty product that will be cheaper than those offered by the current leader. CareFusion followed up the announcement by filing an anti-trust lawsuit against Medtronic, charging that company with using patent protection to create a monopoly in the vertebral compression market. CareFusion – and others in the spinal industry – maintain that Medtronic's patents on the action of kyphoplasty, acquired along with Kyphon Inc. in 2007, have expired, thereby ending the company's exclusive hold on that type of verterbral compression surgery, but CareFusion is the first to act. [See Deal] Finally, CareFusion ended the month with the announcement of its first significant purchase since its spin-out last August, alerting the device industry that a new strategic buyer is in the market. [See Deal]

The three individual events reflect the aggressive attitude CareFusion executives intend to carry now that they're free from Cardinal Health. Analysts say the company needs to increase its revenue growth...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from In Vivo

US Health System Redesign Critical, NAM’s Medical Experts Warn Trump Government

 
• By 

The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.

Podcast: “Powerful Yet Unexplored”: Commit Biologics Tackles The Complement System

 

Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement system for the treatment of serious diseases.

ML-Assisted Genetic Risk Score Predicts GLP-1 Adverse Events

 
• By 

Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.